The o2h human health EIS knowledge-intensive fund IV is the first HMRC approved KI fund in the UK that will invest in EIS seed stage KI companies covering novel drug discovery and AI technologies.

The human health SEIS fund will invest in SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI Technologies.

The o2h human health S/EIS fund is a hybrid fund that is investing in EIS and SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.